E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "In Vitro and In Vivo Approaches in the Driving Seat of Marine Drugs Discovery"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 30 November 2018

Special Issue Editor

Guest Editor
Prof. Mei-Chin Lu

Graduate Institute of Marine Biology, National Dong Hwa University, Taiwan
Website | E-Mail
Interests: structural elucidation; marine secondary metabolites; marine natural products; biological activities; cytotoxic mechanism; in vitro and in vivo assays

Special Issue Information

Dear Colleagues,

Isaac Newton once said, “I don't know what I may seem to the world, but as to myself, I seem to have been only like a boy playing on the sea-shore and diverting myself in now and then finding a smoother pebble or a prettier shell than ordinary, whilst the great ocean of truth lay all undiscovered before me.” Despite three centuries of great scientific discoveries, the truth about oceans and their organisms remains elusive. Natural products, medicinal and synthetic chemists along with pharmacologists, biochemists, cell biologists and microbiologists united their forces to unleash hidden treasures of oceans and seas. New classes of secondary metabolites were discovered from marine organisms with an unprecedented spectrum of biological activities. Several compounds entered the drug pipeline and many others are in various stages of clinical trials. Scientists used all available biological assays to screen marine organism extracts and fractions to zoom in on the most important compounds.

This Special Issue of Marine Drugs entitled “In Vitro and In Vivo Approaches in the Driving Seat of Marine Drugs Discovery” focuses on presenting the most recent advances in biological assays applied for the discovery of marine secondary metabolites with potential biological activities. Full research papers, short notes and review articles reporting the applications of in vitro and in vivo assays to reveal biological activities of marine natural products, will be considered. Colleagues are invited to present their research on biochemical and cell line assays along with pharmacokinetics, pharmacodynamics and disease models. They are also encouraged to present the most recent discoveries in new targets and assays for accelerating the process of drug discovery.

Prof. Mei-Chin Lu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Marine secondary metabolites
  • Biological activities
  • In vitro assays
  • In vivo assays
  • Drug discovery

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Research

Open AccessArticle Lobocrassin B Induces Apoptosis of Human Lung Cancer and Inhibits Tumor Xenograft Growth
Mar. Drugs 2017, 15(12), 378; doi:10.3390/md15120378
Received: 19 September 2017 / Revised: 15 November 2017 / Accepted: 28 November 2017 / Published: 4 December 2017
PDF Full-text (3990 KB) | HTML Full-text | XML Full-text
Abstract
Lobocrassin B, a natural cembrane-type compound isolated from the soft coral Lobophytum crassum, has been shown to have significant biological effects, including anticancer activity. As the most common cause of cancer mortality worldwide, lung cancer remains a major concern threatening human health.
[...] Read more.
Lobocrassin B, a natural cembrane-type compound isolated from the soft coral Lobophytum crassum, has been shown to have significant biological effects, including anticancer activity. As the most common cause of cancer mortality worldwide, lung cancer remains a major concern threatening human health. In the current study, we conducted in vitro experiments to demonstrate the inhibiting effect of Lobocrassin B on CL1-5 and H520 human lung cancer cells growth and to explore the underlying mechanisms, as well as in nude mice bearing CL1-5 tumor xenografts. Lobocrassin B exerted cytotoxic effects on lung cancer cells, as shown by decreasing cell viability, and inducing apoptosis, oxidative stress and mitochondrial dysfunction. In addition, the increased level of Bax, cleaved caspase-3, -9 and -8, and the suppression of Bcl-2 were observed in the Lobocrassin B treated cells. Moreover, in vivo assays verified the significance of these results, revealing that Lobocrassin B inhibited CL1-5 tumor xenograft growth and that inhibitory effects were accompanied by a marked increase in tumor cell apoptosis. In conclusion, the results suggested that Lobocrassin B could be a potential anticancer compound for its propensity to inhibit growth and induce apoptosis in human lung cancer cells. Full article
Figures

Figure 1

Open AccessArticle Anti-Inflammatory Cembranoids from the Soft Coral Lobophytum crassum
Mar. Drugs 2017, 15(10), 327; doi:10.3390/md15100327
Received: 26 September 2017 / Revised: 19 October 2017 / Accepted: 20 October 2017 / Published: 23 October 2017
PDF Full-text (2014 KB) | HTML Full-text | XML Full-text
Abstract
Abstract: Cembrane-type diterpenoids are among the most frequently encountered natural products from the soft corals of the genus Lobophytum. In the course of our investigation to identify anti-inflammatory constituents from a wild-type soft coral Lobophytum crassum, two new cembranoids, lobophyolide
[...] Read more.
Abstract: Cembrane-type diterpenoids are among the most frequently encountered natural products from the soft corals of the genus Lobophytum. In the course of our investigation to identify anti-inflammatory constituents from a wild-type soft coral Lobophytum crassum, two new cembranoids, lobophyolide A (1) and B (2), along with five known compounds (37), were isolated. The structures of these natural products were identified using NMR and MS spectroscopic analyses. Compound 1 was found to possess the first identified α-epoxylactone group among all cembrane-type diterpenoids. The in vitro anti-inflammatory effect of compounds 1–5 was evaluated. The results showed that compounds 1–5 not only reduced IL-12 release, but also attenuated NO production in LPS-activated dendritic cells. Our data indicated that the isolated series of cembrane-type diterpenoids demonstrated interesting structural features and anti-inflammatory activity which could be further developed into therapeutic entities. Full article
Figures

Back to Top